Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum

Core Viewpoint - Nasus Pharma Ltd. is participating in the upcoming virtual Life Sciences Investor Forum, showcasing its innovative intranasal products aimed at treating emergency medical conditions [1]. Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing intranasal powder products for acute medical conditions [3]. - The company's lead product candidate, NS002, is an intranasal powder formulation of Epinephrine, designed as a needle-free alternative to traditional autoinjectors for anaphylaxis treatment [3]. - The proprietary powder-based intranasal (PBI) technology enables rapid and reliable drug delivery, utilizing the nasal cavity's vascular network for quick absorption [3]. - The PBI formulation features uniform spherical powder particles, which may allow for broader dispersion and potentially faster absorption compared to liquid-based nasal products [3]. Presentation Details - Company management will be available for one-on-one meetings during the conference, and interested parties are encouraged to arrange meetings through their conference representative [2]. - The presentation is scheduled for March 11, 2026, at 12:30 p.m. ET, and will be led by CEO Dan Teleman [4].